Simeprevir/pegylated interferon/ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation. (22nd April 2016)

• Record Type: Journal Article
• Authors: Shinoda, Masahiro; Ebinuma, Hirotoshi; Itano, Osamu; Yamagishi, Yoshiyuki; Obara, Hideaki; Kitago, Minoru; Nakamoto, Nobuhiro; Hibi, Taizo; Yagi, Hiroshi; Abe, Yuta; Matsubara, Kentaro; Chu, Po‐sung; Wakayama, Yuko; Taniki, Nobuhito; Yamaguchi, Akihiro; Amemiya, Ryusuke; Miyake, Rei; Mizota, Takamasa; Kanai, Takanori; Kitagawa, Yuko
• Is Part Of: Coloration technology. Volume 131:Number 2(2015)
• Page Start: 1118
• Page End: 1128
• Publication Date: 2016-04-22
• Subjects: calcineurin inhibitor -- direct‐acting antiviral agent -- living donor liver transplantation -- recurrent hepatitis C -- simeprevir -- virological response; Color -- Periodicals; Color in the textile industries -- Periodicals; Dyes and dyeing -- Periodicals; 667
• DOI: 10.1111/hepr.12666
• Languages: English
• ISSNs: 1472-3581

Abstract

Abstract : Aim: Simeprevir (SMV) is a protease inhibitor which demonstrates good tolerability and high antiviral response in patients with hepatitis C. The clinical outcomes of triple therapy using simeprevir, pegylated interferon and ribavirin (SMV/PEG IFN/RBV) for recurrent hepatitis C after living donor liver transplantation (LDLT) have not been well reported. In this study, we assessed the outcomes of patients with recurrent hepatitis C (genotype 1) after LDLT who received triple therapy at our hospital. Methods: SMV/PEG IFN/RBV was administrated for 12 weeks (triple therapy), followed by another 12 weeks or extended period of PEG IFN/RBV (dual therapy). Virological response, interaction with calcineurin inhibitors and adverse events were retrospectively analyzed. Results: Ten patients with recurrent hepatitis C after LDLT completed 12 weeks of triple therapy. Nine patients achieved rapid or early virological response, and one patient was a non‐responder. The nine responders received subsequent dual therapy, and the duration of dual therapy was extended (24 to 36 weeks) in five cases. Although one patient was in relapse 8 weeks after completing the standard duration (12 weeks) of dual therapy, eight patients achieved sustained virological response for 12 weeks (SVR12). The SVR12 rate was 80%. Trough levels of calcineurin inhibitor did not show marked changes after introduction of SMV in all cases. There were no major adverse events associated with SMV. Conclusion: SMV treatment may be a safe and effective option for recurrent hepatitis C after LDLT.